SecSonar.com

NovoCure Limited (NVCR)

NovoCure Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

NovoCure Limited (NVCR) is a Medical - Instruments & Supplies company based in JE with a market capitalization of $2B. Revenue grew 8.3% year-over-year and free cash flow was negative at -$75.7M. This page tracks NVCR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

JE · 1.49K employees · IPO Oct 1, 2015

Valuation

Valuation & price

$17.58 · as of May 17, 2026 · -4.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.84

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$18.31$14.17$10.03Jul 25Dec 25Jul 26Jul 7, 25$16.89Jul 9, 25$18.19Jul 11, 25$17.60Jul 15, 25$16.79Jul 17, 25$16.21Jul 21, 25$16.10Jul 23, 25$16.51Jul 25, 25$12.04Jul 29, 25$11.38Jul 31, 25$11.57Aug 4, 25$11.76Aug 6, 25$11.39Aug 11, 25$10.90Aug 13, 25$11.62Aug 15, 25$11.73Aug 19, 25$12.07Aug 21, 25$11.91Aug 25, 25$11.70Aug 27, 25$11.91Aug 29, 25$12.33Sep 3, 25$12.08Sep 5, 25$12.28Sep 9, 25$12.66Sep 11, 25$12.73Sep 16, 25$12.68Sep 18, 25$13.00Sep 22, 25$13.09Sep 24, 25$12.84Sep 26, 25$12.89Sep 30, 25$12.92Oct 2, 25$14.05Oct 6, 25$14.50Oct 8, 25$14.35Oct 10, 25$13.49Oct 14, 25$13.17Oct 16, 25$14.03Oct 21, 25$14.13Oct 23, 25$13.92Oct 27, 25$13.58Oct 29, 25$13.48Oct 31, 25$12.81Nov 4, 25$12.00Nov 6, 25$11.27Nov 10, 25$11.27Nov 12, 25$11.36Nov 14, 25$11.32Nov 18, 25$11.45Nov 20, 25$11.46Nov 25, 25$12.64Nov 28, 25$12.81Dec 2, 25$10.92Dec 4, 25$11.76Dec 8, 25$12.06Dec 10, 25$13.22Dec 12, 25$13.32Dec 16, 25$12.93Dec 18, 25$12.56Dec 22, 25$13.44Dec 24, 25$13.44Dec 29, 25$13.27Jan 2, 26$13.12Jan 6, 26$14.29Jan 8, 26$14.87Jan 12, 26$14.18Jan 14, 26$13.77Jan 16, 26$13.64Jan 21, 26$13.56Jan 23, 26$13.45Jan 27, 26$13.05Jan 29, 26$12.38Feb 2, 26$12.19Feb 4, 26$11.56Feb 9, 26$10.03Feb 11, 26$10.50Feb 13, 26$10.99Feb 18, 26$11.40Feb 20, 26$11.36Feb 24, 26$11.74Feb 26, 26$13.75Mar 2, 26$13.52Mar 4, 26$13.42Mar 6, 26$13.04Mar 10, 26$12.75Mar 12, 26$12.01Mar 17, 26$12.35Mar 19, 26$12.15Mar 23, 26$11.82Mar 25, 26$11.61Mar 27, 26$10.97Mar 31, 26$10.90Apr 2, 26$10.55Apr 7, 26$10.35Apr 9, 26$11.00Apr 13, 26$10.72Apr 15, 26$12.17Apr 17, 26$12.83Apr 22, 26$13.02Apr 24, 26$12.47Apr 28, 26$12.12Apr 30, 26$15.21May 4, 26$16.93May 6, 26$16.50May 8, 26$17.89May 12, 26$18.31May 14, 26$18.05May 18, 26$17.46May 20, 26$17.75May 22, 26$17.96May 28, 26$17.25Jun 1, 26$16.56Jun 3, 26$16.15Jun 5, 26$17.16Jun 9, 26$17.24Jun 11, 26$17.71Jun 15, 26$17.60Jun 17, 26$17.85Jun 22, 26$13.61Jun 24, 26$14.72Jun 26, 26$15.43Jul 2, 26$17.20
$10.0352-week range$18.46
Loading valuation history…

Fundamentals

Key fundamentals

$2B

Market cap

8.3%

Revenue growth (YoY)

74.5%

Gross margin

-$75.7M

Free cash flow (USD)

-$167.5M

Net debt

Net cash position

3.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$82.9MFY 2017$177.0MFY 2018$248.1MFY 2019$351.3MFY 2020$494.4MFY 2021$535.0MFY 2022$537.8MFY 2023$509.3MFY 2024$605.2MFY 2025$655.4M
$82.9M$655.4M

Free cash flow by year

2016 → 2025

FY 2016$-125.3MFY 2017$-40.5MFY 2018$-8.6MFY 2019$16.1MFY 2020$84.2MFY 2021$58.6MFY 2022$9.4MFY 2023$-100.4MFY 2024$-69.2MFY 2025$-75.7M
-$125.3M-$75.7M

Gross margin by year

2021 → 2025

FY 202178.5%FY 202278.6%FY 202374.8%FY 202477.3%FY 202574.5%
78.5%74.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCE Mark ApprovalJun 30, 2026Filing
  • 8-K eventPhase 3 Trial ResultsJun 18, 2026Filing
  • Insider sellInsider Sell $615KLeonard Frank X · Chief Executive Officer · $614.6KJun 5, 2026Filing
  • 8-K eventIncentive Plan AmendedJun 5, 2026Filing
  • Insider sellInsider Sell $46KHung David · Director · $46.4KJun 3, 2026Filing
  • Insider sellInsider Sell $46KVERNON W ANTHONY · Director · $46.4KJun 3, 2026Filing
  • Insider sellInsider Sell $46KHILLEMAN JERYL L · Director · $46.4KJun 3, 2026Filing
  • Insider sellInsider Sell $46KScannell Timothy J · Director · $46.4KJun 3, 2026Filing
  • Insider sellInsider Sell $46KOcean Allyson J · Director · $46.4KJun 3, 2026Filing
  • Insider sellInsider Sell $46KStafford Kristin · Director · $46.4KJun 3, 2026Filing

Questions

Frequently asked questions

What is NovoCure Limited's market cap?

NovoCure Limited (NVCR) has a market capitalization of $2B.

What is NVCR's P/E ratio?

A meaningful P/E ratio is not available for NVCR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NVCR's price-to-book (P/B) ratio?

NVCR trades at 5.84 times book value per share.

Are insiders buying NVCR stock?

SEC Form 4 filings show no open-market insider buys at NovoCure Limited in the last 90 days (8 sells).

Same arena

Related companies in Medical - Instruments & Supplies

XRAY

DENTSPLY SIRONA Inc.

$2.1B

LMAT

LeMaitre Vascular, Inc.

$2.2B

PLSE

Pulse Biosciences, Inc.

$1.8B

NNNN

Anbio Biotechnology Class A Ordinary Shares

$1.5B

STAA

STAAR Surgical Company

$1.5B

ATRC

AtriCure, Inc.

$1.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.